Price
No data yet.
Social Signal Score
Analyst Ratings
19 analystsRevenue
$22.0K-99.01%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Anthony S. Marucci
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 198
- Beta
- 0.84
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 18.55
Financials
Revenue
$22.0K-99.0%Net Income
$-73.50MEBITDA
$-72.60MFree Cash Flow
$-60.59MEPS (diluted)
$-0.94Shares Outstanding (diluted)
77.84M+1059.8%Operating Expenses
$80.65MCash & Debt
$717.59MRevenue by Segment (annual)
$1.54MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.50M | $-258.80M | $-3.90 |
| 2024 | $7.02M | $-157.86M | $-2.45 |
| 2023 | $6.88M | $-141.43M | $-2.92 |
| 2022 | $2.36M | $-112.33M | $-2.40 |
| 2021 | $4.65M | $-70.51M | $-1.64 |
| 2020 | $7.42M | $-59.78M | $-2.02 |
| 2019 | $3.57M | $-50.88M | $-3.51 |
| 2018 | $9.54M | $-151.18M | $-14.48 |
| 2017 | $12.74M | $-93.03M | $-10.86 |
| 2016 | $6.79M | $-128.53M | $-18.99 |
| 2015 | $5.48M | $-127.20M | $-19.66 |
| 2014 | $3.59M | $-118.08M | $-19.81 |
| 2013 | $4.11M | $-81.55M | $-15.33 |
| 2012 | $11.20M | $-59.12M | $-15.37 |
Valuation
CLDXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-40.00%Social Signal Score
Mentions (2)
- Newsreuters.com·5h ago·Negative
Celldex's skin disease drug meets goals in two late-stage trials Celldex Therapeutics said on Tuesday its experimental drug for a skin disease met the main and secondary goals of two late-stage trials.
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
Celldex to Present at Upcoming Investor Conference HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET.
View source ↗
Earnings
Mon, Nov 9(in 7 weeks)
Consensus estimate $-1.02 per share
Typical surprise -2.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.94 vs $-1.06beat
- Thu, May 7$-1.18 vs $-1.15miss
- Wed, Feb 25$-1.22 vs $-1.00miss
- Mon, Nov 10$-1.01 vs $-0.88miss
- Thu, Aug 7$-0.85 vs $-0.86beat
- Thu, May 8$-0.81 vs $-0.75miss
Estimates and results for CLDX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CLDX officers and directors.
- Bought
- $308k
- Sold
- $8.0m
1 trade
10 trades
- Jimenez Freddy A.sold
- Wright Richard M.sold
- Jimenez Freddy A.sold
- Jimenez Freddy A.sold
- Marucci Anthony Sbought
- Martin Samuel Batessold
- Crowley Elizabethsold
- Crowley Elizabethsold
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CLDX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.